Polsinelli’s Private Equity practice advises private equity sponsors, portfolio companies and management teams in all aspects of the private investment life cycle. With a team of more than 120 attorneys, we have represented hundreds of private equity funds and portfolio companies in transactions worth several billions of dollars.

Members of our Private Equity practice advise every stage of the private investment life cycle from fund formation, investment and M&A activity, debt financings (including private credit and bank financings), equity financings, recapitalizations, special situations, and daily counsel to dispositions and exits. Our cross-disciplinary and business-minded attorneys leverage their unique skills to help clients take the next step in growing their businesses.

Our attorneys have advised clients across most industries comprising the S&P 500 and are equipped to understand and navigate industry-specific complexities. Polsinelli has substantial experience in the health care, real estate and technology industries with the majority of our M&A transactions ranging from $25 million to $1 billion in enterprise value.

Private Equity services

  • Fund formation, fund compliance and private offerings
  • Portfolio company investments, M&A and dispositions, including control and minority transactions, leveraged buyouts and roll-ups 
  • Equity and senior secured and mezzanine debt financings
  • Special situations
  • Outside general counsel portfolio company representation
  • Primary and secondary equity and debt capital funding, including offerings and PIPE funding

Funds and Investments services

  • Early-Stage
  • Venture Capital
  • Venture Debt
  • Growth
  • Control

Recent Private Equity firm rankings include:

  • Nationally ranked among the top 25 law firms in Private Equity deals by PitchBook 2024 Global League Tables
    • Most Active Law Firm in the U.S.
    • Most Active Representing U.S. Companies
    • Most Active Representing Global Companies
    • Most Active Representing U.S. Investors
  • Recognized as a top 25 law firm for Private Equity activity by PitchBook 2024 in the following sectors and deal types:
    • Most Active in B2C Sector
    • Most Active in B2B Sector
    • Most Active in Healthcare Sector
    • Most Active in Buyouts
    • Most Active in Other PE Deals
Publications
All Publications
FDA turmoil reshapes biotech dealmaking terms
Shareholder Chris Simpson discusses how ongoing uncertainty and instability at the FDA is reshaping the structure and negotiation of biotech and pharma deals. (subscription required)
Read More
Demystifying Private Equity in Healthcare
Shareholder Ashley Osak joins Voices in Health Law to break down what private equity transactions mean for health care organizations. She examines the types of deals investors are pursuing, the growing scrutiny from state regulators, and what’s ahead for private equity in the sector.
Read More